Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.
Hepatic Carcinoma, Hepatic Metastasis
About this trial
This is an interventional prevention trial for Hepatic Carcinoma
Eligibility Criteria
Inclusion Criteria: Patients diagnosed with hepatic lesions who are going to undergo hepatectomy via laparoscopy. The patient must be between 18 and 80 years old. The patient, or his/her representative, has given his/her consent to participate in the study. The patient must, in the opinion of the investigator, be able to comply with all the requirements of the clinical trial. The patient must not be allergic to the drug. Exclusion Criteria: History of hypersensitivity to the drug to be administered. Children under 18 years of age. Urgent intervention. Intervention performed in an open manner (not laparoscopic). Patient's refusal to participate in the study. Contraindication to receive octreotide. Women of childbearing age (those women who are in the period between menarche and menopause). Having to present a negative pregnancy test to take part in the study. Pregnant or lactating women, given the absence of studies of this drug in this patient profile.
Sites / Locations
- Clinica Universidad de NavarraRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Treatment arm (octreotide)
Placebo arm (saline solution)
This patient will receive the treatment: Octreotide charge 100 mcgr + continuous infusion during the surgery 25 mcgr/h
This patient will receive physiologic saline solution at the same infusion